This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (19)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Thrombolysis  • Cardiovascular System  • Review  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Peter J. Zed, PharmD; James E. Tisdale, PharmD; Steven Borzak, MD

Arch Intern Med. 1999;159:1849-1857.

Acute coronary syndromes (unstable angina and non–Q-wave myocardial infarction) are caused by the rupture of an atherosclerotic plaque, platelet activation, and fibrin deposition resulting in thrombosis. Aspirin and unfractionated heparin have traditionally been the treatments of choice for patients with acute coronary syndromes. Low-molecular-weight heparins offer potential advantages over unfractionated heparin, having proven equally effective for the treatment and prevention of many thromboembolic processes. Recently, a number of randomized controlled trials have been conducted to evaluate the role of low-molecular-weight heparins in the management of patients with unstable angina or non–Q-wave myocardial infarction. The purpose of this article is to review and evaluate the available literature on the use of low-molecular-weight heparins in the management of acute coronary syndromes to establish their role in therapy.

From CSU Pharmaceutical Sciences, Vancouver Hospital and Health Sciences Center, and the Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver (Dr Zed); and the Department of Pharmacy Practice, College of Pharmacy and Allied Health Professions, Wayne State University and Department of Pharmacy Services (Dr Tisdale), and the Cardiac Intensive Care Unit, Division of Cardiovascular Medicine (Dr Borzak), Henry Ford Hospital, Detroit, Mich.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Internal Medicine Reader's Choice: Continuing Medical Education
Arch Intern Med. 1999;159(16):1961-1962.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Congestive Heart Failure
POPPAS and ROUNDS
Am. J. Respir. Crit. Care Med. 2002;165:4-8.
FULL TEXT  

Thigh Hematoma After Femoral Venipuncture in a Patient Treated With Low-Molecular-Weight Heparin
Kumar and Solti
Arch Intern Med 2001;161:1113-1114.
FULL TEXT  

Antithrombotic Therapy in Patients With Acute Coronary Syndromes
Levine et al.
Arch Intern Med 2001;161:937-948.
ABSTRACT | FULL TEXT  

Safety and Cost of Low-Molecular-Weight Heparin as Bridging Anticoagulant Therapy in Subacute Cerebral Ischemia
Kalafut et al.
Stroke 2000;31:2563-2568.
ABSTRACT | FULL TEXT